Published in Medical Letter on the CDC and FDA, June 6th, 2010
"We report the results of the up-to-60-week open-label phase following the double-blind phase. Participants received open-label memantine and were escalated to a 40 mg/day dose or their maximum tolerated dose in the double-blind phase. Adverse experiences were used to evaluate safety, and changes in the mean of eight...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA